Neuropeptides are important signalling molecules in the brain and alterations in their expression levels have been linked to neurological disorders such as Parkinson's disease. It is challenging to map neuropeptide changes across and within brain regions because of their low in vivo concentrations and complex post-translational processing. Consequently, the role of neuropeptides in Parkinson's disease is not well understood. Thus, we have developed and validated a method to image multiple neuropeptides simultaneously in both rat and primate brain tissue sections by matrix-assisted laser desorption-ionisation mass spectrometry imaging at high lateral resolution. Using a unilateral 6hydroxydopamine rat model of Parkinson's disease, we imaged changes in enkephalins, dynorphins, tachykinins and neurotensin associated with the dopaminergic denervation and L-DOPA treatment in multiple brain regions. L-DOPA administration significantly affected neuropeptides in the globus pallidus, while neuropeptides in the caudate-putamen were mostly affected by dopamine depletion.
Optimisation of imaging methods to improve understanding of neuropeptide signalling in specific brain structures is highly important to fully elucidate their roles in PD and aid development of new treatments. Some widely applied techniques have severe limitations for mapping the abundance and distributions of neuropeptides within brain regions in such cases. For example, the information provided by in situ hybridisation is limited by the complex post-translational processing of neuropeptides, while immunochemical analyses are hindered by the possibilities of antibodies crossreacting with similar neuropeptides and the limited number of neuropeptides that can be simultaneously analysed.
One method that can overcome some of the challenges of neuropeptide research is matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). This label-free technique is used to map distributions and relative quantities of molecules in tissue sections. Because MALDI-MSI is not limited by molecular labelling, thousands of molecules can be imaged in a single experiment, so it is suitable for simultaneously mapping multiple neuropeptides in a single section. Furthermore, MALDI-MSI can distinguish between neuropeptides with similar amino acid sequences and posttranslational modifications, and has the potential to map uncharacterised neuropeptides. However, although MALDI-MSI of neuropeptides has been successful in some studies, mapping neuropeptides by MSI in the mammalian brain remains challenging due to the low concentrations of these molecules (Guenther et al., 2011; Hanrieder et al., 2011; Kallback et al., 2012; Ljungdahl et al., 2011) .
Here, we report a MALDI-MSI approach that allows visualisation of neuropeptide distributions across the brain, focusing on dynorphins, enkephalins, tachykinins and neurotensin. This method affords high lateral and high mass resolution imaging, enabling the mapping of over 20 neuropeptides across the brain simultaneously. As shown here, we have applied this method to provide reproducible maps of neuropeptide distributions in primate and rat brains, and to characterize alterations of neuropeptides in were treated with L-DOPA/benserazide (10/7.5 mg/kg, i.p.) or saline (control) for two weeks. The rats were sacrificed 30 min after the last injection of L-DOPA. Their brains were removed and flash-frozen in isopentane cooled with dry ice, then stored at −80°C until needed.
Tissue sample preparation for MALDI-MSI
The frozen brain samples were sectioned using a cryostat microtome (Leica CM1900, Leica Microsystems, Wetzlar, Germany). The primate and rat brains were sectioned at thicknesses of 12 and 10 μm, respectively. Tissue sections were thaw-mounted onto indium tin oxide-coated (ITO) glass slides (Bruker Daltonics, Bremen, Germany) and stored at -80°C until analysis.
Tissue washing
Prior to tissue washing, slides with mounted brain sections were removed from -80 °C storage. The slides with the rat brain sections were then immediately dried in a desiccator for 1 hour (h). However, the slides with the macaque brain sections were incubated at -20°C for 2 h before drying in a desiccator for 1 h To compare effects of tissue washing methods on delocalization of neuropeptides, five neuropeptide standards -SP (1-7), SP (1-11), Met-enk, Leu-enk and neurotensinwere prepared at a concentration of 0.1 mg/ml in 0.1% trifluoracetic acid (TFA) in water. This stock solution was diluted 1:10 in 0.1% TFA in water and then further serially diluted 1:5 four times. Each concentration was spotted on rat brain section at a volume of 0.2 μl as well as a control spot of 0.1% TFA. The spots were dried fully before performing tissue washing.
To optimise the tissue washing procedure, five protocols applied in previous studies were validated for use in the planned experiments (Hanrieder et al., 2012; Seeley et al., 2008) ( Supplementary Table 1 ).
All tissue washes were performed by fully immersing the slide in a petri dish containing 45 ml of each wash solution. The petri dish was swirled gently throughout the duration of the washes. The slide was dried between each wash solution. After immersing the slide in the final wash solution of each protocol, it was immediately placed in a desiccator and dried for 15 min.
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Matrix application protocols
A matrix of 2, 5-dihydroxybenzoic acid (DHB) was used in all experiments reported here. For matrix preparation and application for optimal neuropeptide extraction, DHB was used at a concentration of 25 mg/ml in a solution of 50% acetonitrile, 50% water and 0.2% TFA. The matrix was applied using an automated matrix sprayer (TM sprayer, HTX Technologies), at 85°C, with a gas pressure of 6 psi, pump flow rate of 120 μl/min, velocity of 1100 mm/min for four passes, and 2 mm track spacing.
In the drier matrix application protocol for higher lateral resolution neuropeptide imaging, 35 mg/ml of DHB dissolved in of 50% acetonitrile, 50% water and 0.2% TFA, was used. The matrix was applied at 95 °C, with a gas pressure of 6 psi, pump flow rate of 70 μl/min, velocity of 1100 mm/min for six passes and 2 mm track spacing.
MALDI-MSI
A rapifleX MALDI-TOF/TOF system was used in most MALDI-MSI imaging experiments, and a solariX 7T 2ω MALDI-FT-ICR system (all from Bruker Daltonics) for the validation of neuropeptide identity. The mass spectrometers used were equipped with a Smartbeam II 2kHz laser (Ultraflextreme and Solarix) or Smartbeam 3D 10 kHz laser (rapifleX) and all analyses were performed in positive ion mode. The laser power was optimised at the start of each experiment. When using the rapifleX system, 400 laser shots were used at each sample position in high lateral resolution experiments and 1805 laser shots in 100 μm spatial resolution experiments. When using the solariX system 100 laser shots were collected per spot. Data were acquired across the m/z ranges of 450-3000 and 450-5000 in MALDI-TOF and MALDI-FTICR analyses, respectively. MSI data from both TOF and FT-ICR analyses were visualized using FlexImaging (Bruker Daltonics, version 4.1). FT-ICR spectra were normalized against the root mean square (RMS), while TOF/TOF spectra were normalized against the total ion current (TIC). DataAnalysis (Bruker Daltonics, version 4.2) was used to analyse mass spectra and produce mass spectra images.
Sample reproducibility
To test the reproducibility of the tissue washing, four ITO slides were prepared with four consecutive rat brain sections per slide. Each slide was individually submerged in a petri dish containing 45 ml of J o u r n a l P r e -p r o o f Journal Pre-proof 100% chloroform for 30 seconds, with gentle swirling and continual movement of the slide in the chloroform throughout the wash. The chloroform was changed between washing each slide. For MSI analysis, two slides were imaged at a time. Following MSI analysis of all four slides the data from both imaging experiments were uploaded to SCiLS Lab version 2019b (Bruker Daltonics). The maximum intensity value of several peptides was generated from the average spectra from each brain section. These values were used to calculate the coefficient of variation (SD/mean*100), to assess the variation between the four slides, which was then compared to the variation within each slide, as the washing should not have differing effects on tissue sections on the same slide.
Statistical analysis of neuropeptide alterations in an animal model of Parkinson's disease
SCiLS Lab version 2019b (Bruker Daltonics) was used to export maximum intensity values from the average spectrum generated for each neuropeptide in each region of interest in brains from each of the analyzed groups. These values were used for multivariate data analysis (MVDA) and two-way ANOVA to characterize effects of 6-OHDA lesioning and L-DOPA treatment on neuropeptide profiles. MVDA was implemented in SIMCA v.13.0 (Sartorius Stedim Biotech, Umeå, Sweden) with default mean centring and auto-scaling to unit variance settings. Principal component analysis (PCA) was initially applied to acquire an overview of the data and identify strong outliers. Subsequently, partial least squares-discriminant analysis (PLS-DA) was applied to reveal specific differences among the four groups. The variable influence on projection, VIP, and loading values were taken into consideration when evaluating contributions of the included peptides. The models were validated with permutation test (100 permutations) sets.
Statistical analysis was performed using GraphPad Prism version 7.04 (GraphPad Software, La Jolla, California, USA), for individual neuropeptide alterations in the 6-OHDA-and L-DOPA treated groups. Two-way ANOVA was performed with significance levels set at 0.05 and a Sidak's multiple comparisons test was subsequently performed if a significant interaction was detected.
Liquid chromatography -MS sample preparation, analysis and database searching
Fresh frozen primate or rat brains were sectioned using a CM1900 cryostat microtome (Leica Microsystems, Wetzlar, Germany) at -20°C and 300 μm thickness. Tissue punches were collected J o u r n a l P r e -p r o o f Journal Pre-proof from various brain regions. To minimize post-mortem degradation, fresh frozen samples were stabilized at 95°C on a heat stabilizer system (Stabilizor T1, Denator, Sweden). Samples were homogenized in 7.5 μl per mg of cold 0.25% (v/v) aqueous acetic acid by sonication, followed by centrifugation for 40 min at 14 000 x g and 4°C. Each supernatant was filtered using a centrifugal filter device (Millipore, Bedford, MA, USA) with a 10 kDa cut-off membrane and centrifugation for 90 min at 14 000 x g at 4°C. The resulting filtrate was stored at -80°C before analysis.
Peptides were identified using a Q-TOF mass spectrometer (Synapt G2-Si, Waters, Manchester, UK) coupled to a nano-liquid chromatography system (nanoAcquity, Waters) with an electrospray ionization interface. Sample filtrates were pooled and 5 μL portions of the pooled filtrate were injected. Peptides were trapped on a trap column (Symmetry C18, 100 Å, 5 μm, 180 μm x 20 mm, Waters) and then separated on an analytical column (Peptide BEH C18, 130Å, 1.7 μm, 75 μm x 100 mm, Waters) using a 70 min gradient starting with 97% solvent A (0. 25% aqueous acetic acid) and 3% solvent B (acetonitrile) and ending with 10% solvent A and 90% solvent B (flow rate 0.30 μl/min and source temperature 80°C). Data were collected using a data dependent acquisition method in resolution mode. A full scan was performed followed by tandem MS (MS/MS) of the 10 most intense ions. Collision energy was ramped depending on the mass of the peptides, the fragmented masses were then excluded of the next 30 seconds to prevent them from being fragmented again. Glu-1-Fibrinopeptide B was added for calibration prior to analysis and leucine-enkephalin (Leu-enk) was used as lock mass during data acquisition. Raw data were converted to Mascot Generic Format and searched using X! Tandem against the following databases: human precursors SwePep and UniProt Macaca mulatta for primate analysis; and uniprot Mus musculus and Rattus norvegicus, for rat analysis.
Nissl Staining
Tissue sections were subjected to Nissl staining after MALDI-MSI analysis, as follows. Matrix was removed and the tissues were fixed in two successive 5-minute washes in 100 % ethanol. The slides were then allowed to dry for 5 min, washed in water for 1 min and stained with cresyl violet solution (0.1 % in water and 0.25 % acetic acid) for 10 min. This was followed by multiple tissue washing J o u r n a l P r e -p r o o f Journal Pre-proof
Results

Mapping neuropeptides in primate and rat brains
We developed a novel method of sample preparation for MALDI-MSI neuropeptide imaging that enabled us to simultaneously map 25 neuropeptides in the primate brain and 20 neuropeptides in the rat brain (Table 1 , Figs. 1 and 2). To our knowledge, this is the highest number of neuropeptides that have been mapped across the brain simultaneously. The developed method reduced interfering peaks, improved signal to noise ratios, did not cause visible delocalisation of neuropeptides ( Supplementary   Fig. 1 ), and provided reproducible results (Supplementary Table 2 ). The neuropeptides imaged in the primate and rat brains were initially identified using the accurate mass information provided by MALDI-Fourier transform ion cyclotron resonance (FTICR) mass spectrometry (Table 1 and Supplementary Figs. 3 and 4) and most of the neuropeptides were subsequently verified by liquid chromatography (LC)-MS/MS analyses (Table 1 and Supplementary Fig. 5 ).
In the primate brain, the method enabled imaging of multiple neuropeptides, including 11 derived from the proenkephalin (PENK) precursor: leucine-enkephalin (Leu-enk), four extended forms of methionine-enkephalin (Met-enk), and six others (Fig. 1a ). The PENK peptides were most abundant in the external segment of globus pallidus (GPe), but several enkephalins were also detected at lower abundance in the internal segment of the globus pallidus (GPi), putamen (Put) and caudate nucleus.
Met-enk-RGL was the most abundant form of Met-enk in the GPi (Fig. 1a ). However, it should be noted that the tachykinin neuropeptide SP (1-7) and Met-enk-RGL have very similar mass-to-charge (m/z) ratios (900.505 and 900.440, respectively) and MALDI-TOF analysis cannot distinguish between these two neuropeptides. Therefore, an additional imaging technique, MALDI-FTICR, was used to resolve the Met-enk-RGL and SP (1-7) neuropeptides, and the results showed that Met-enk-RGL and SP (1-7) were primarily localized in the GPe and GPi, respectively ( Fig. 1, Supplementary   Fig. 3 ).
Overall, seven neuropeptides from the prodynorphin (PDYN) precursor were imaged (Fig. 1b ). Supplementary Fig. 5 ).
The tachykinin neuropeptides, Neurokinin A (NK A), SP (1-11) and SP (1-9) ( Fig. 1c) , were detected and highly abundant in the GPi, but SP (1-11) was also detected at lower levels in discrete patches in the GPe, Put and caudate nucleus. Other detected neuropeptides included: somatostatin 28 (SST 28)
(1-12), localised in the amygdala and stria terminalis; , detected in the GP, Put and caudate nucleus; and oxytocin and R-vasopressin, detected in a discrete area of the lateral hypothalamus (LH) (Fig. 1d ).
The neuropeptides in coronal rat brain sections, -2.16 mm from bregma (Paxinos and Watson, 2014) , were also imaged by MALDI-TOF (Fig. 2) . Enkephalins were mainly detected in the GP (Fig. 2a ).
The dynorphins were most abundant in a small area of the lateral hypothalamus, but were also present at low levels in the hippocampus (Fig. 2b) . The tachykinins were present across the hypothalamus ( Fig. 2c ). However, fewer neuropeptides were detected in the rat brain than in the primate brain. For example, Leu-enk, Dyn A (1-8) and α-Neo (3-10) were not detected in rat brain. The discrepancies may have been due to low concentrations of these neuropeptides at the coronal levels analysed.
Alternatively, Dyn A (1-8) and α-Neo (3-10) may be degradation products that were only detected in sections of the primate brains because of their longer post-mortem intervals before preparation. The neuropeptide R-vasopressin was detected in the arcuate nucleus of the hypothalamus in the rat brain ( Fig. 2d ). Somatostatin 28 (1-12) was also present across the hypothalamus and PEP-19 (48-62) was most abundant in the caudate-putamen (CPu) and GP (Fig. 2d ). Neurotensin could not be resolved by MALDI-TOF. However, MALDI-FTICR imaging revealed the presence of neurotensin (Table 1 , Supplementary Fig. 4 ) in the LH of the rat brain, although this neuropeptide was not detected in the primate brain by either imaging technique.
High lateral resolution imaging of neuropeptides
The matrix application protocol was developed to detect the highest possible number of neuropeptides.
However, this method caused the production of relatively large matrix crystals, and was thus only Therefore, a drier matrix application protocol was developed to enable imaging with higher lateral resolution, and applied to acquire images of neuropeptides in primate ( Fig. 3a) and rat (Fig. 3b ) brains with 25 µm and 15 μm lateral resolution, respectively. Not all neuropeptides could be detected using this protocol, but the higher lateral resolution imaging of neuropeptides in the primate brain revealed that Met-enk-RF and PENK (218-227) were most abundant in parts of the substantia innominata. SP
(1-11) and were also detected at higher lateral resolution.
High lateral resolution imaging of the rat brain revealed localisation of neuropeptides in specific layers of the hippocampus (Fig. 3b ). α-Neo was localised to the stratum lucidum of the CA3 region of the hippocampus and polymorph layer of the dentate gyrus. Somatostatin was more abundant in the molecular layer of the dentate gyrus and the stria terminalis. Furthermore, SP 1-11 was localised to the lateral hypothalamic area and Met-enk to areas of the GP and the amygdala.
Neuropeptide alterations caused by unilateral 6-OHDA lesioning and L-DOPA administration in a rat model of PD
The optimised MALDI-MSI method was employed to demonstrate neuropeptide alterations in an animal model of PD. The MALDI-MSI analysis was performed on two groups: unilateral 6-OHDA lesioned rats with and without L-DOPA administration (Fig. 4a ). Multivariate data analysis (MVDA) was then applied to determine whether the groups could be separated by differences in neuropeptide abundances. Partial least squares discriminant analysis (PLS-DA) models were developed for the GP and CPu (Fig. 4b ), using the ion intensities extracted from the MALDI-MSI analysis for 18 identified neuropeptides.
The t-scores for the first principal component (PC, t[1] ) obtained from analysis of the GP data significantly discriminated between neuropeptide profiles of the saline-and L-DOPA-treated groups (p≤0.0001). In addition, scores for the second PC (t[2]) significantly discriminated between the unlesioned and lesioned sides of the brain in the L-DOPA-treated groups (p≤0.01), but not in the saline-administered animals, demonstrating significant effects of L-DOPA treatment on neuropeptide levels in the GP. Similarly, t-scores for the first PC (t[1]) obtained in PCA of the CPu data J o u r n a l P r e -p r o o f Journal Pre-proof significantly separated neuropeptide profiles in lesioned and unlesioned sides of the brains (p≤0.0001), and t-scores for the second component (t[2] ) discriminated between saline-and L-DOPA-treated animals in the lesioned side of the brain (p≤0.001). However, L-DOPA had no effect on the unlesioned hemisphere. Loading plots from the PLS-DA analysis were further used to identify differences in neuropeptide levels related to the treatments ( Supplementary Fig. 6 ). Increased levels of PDYNderived neuropeptides were associated with the lesioned hemisphere of the L-DOPA-treated animals in both the GP and CPu. Increased levels of many PENK-derived neuropeptides were associated with the lesioned hemisphere of the saline-administered animals, mainly in the CPu but also (for some of these neuropeptides) the GP. Furthermore, decreased levels of SP (1-11) in the GP were associated with the lesioned hemisphere of the L-DOPA-treated animals.
Ion intensities extracted for each of the 18 neuropeptides of interest were subjected to two-way ANOVA. Neuropeptide levels in the LH, which could not be analysed by PLS-DA because of the low number of detected neuropeptide alterations, were also analysed individually using two-way ANOVA.
MALDI-MS images of distributions of a representative enkephalin (met-enk-RF), a dynorphin (dynorphin B), a tachykinin (SP 1-11), and neurotensin are shown, together with corresponding twoway ANOVA results for the three analysed brain regions (GP, CPU and LH), in Figure 4c -f. Levels of the enkephalin, Met-enk-RF, were significantly higher (p≤0.001) in the GP and CPu of lesioned hemispheres than in the contralateral unlesioned hemispheres. Met-enk-RF levels were significantly higher in the LH of lesioned hemispheres than in contralateral sides in the saline-administered rats (p≤0.001), but not the L-DOPA-treated animals. Effects of the treatments on other PENK-derived neuropeptides differed from those on Met-enk-RF. Levels of three PENK derived neuropeptides were significantly decreased by L-DOPA treatment ( Supplementary Fig. 7) . Dynorphin B levels were significantly higher in the GP and CPu of the lesioned hemispheres of L-DOPA-treated rats (Fig. 4d) than in their unlesioned hemispheres (p≤0.001 and p≤0.01, respectively), and lesioned hemispheres of the saline-treated rats (p≤0.0001 and p≤0.001). Dynorphin B levels were also lower in the LH of lesioned hemispheres of the saline-treated rats than in their unlesioned hemispheres (p≤0.05). SP (1-11) levels were significantly lower in the GP and LH of lesioned hemispheres of both L-DOPA-and J o u r n a l P r e -p r o o f
Discussion
The results presented here demonstrate the efficacy of MALDI-MSI for simultaneously mapping over 20 neuropeptides in either primate or rat brains. The methods developed and employed allowed reproducible neuropeptide imaging at high lateral resolution without delocalisation of endogenous neuropeptides. Additionally, MALDI-MSI was used for the successful detection of multiple neuropeptide alterations in specific brain regions in an animal model of PD.
Neuropeptides in the mammalian brain are challenging to study using MALDI-MSI due to their low concentrations, although they have been successfully mapped in rat tissue by MALDI-MSI in previous studies. For instance, oxytocin and vasopressin have been localised to discrete regions of the pituitary gland, dynorphin and enkephalin neuropeptides have been imaged in the spinal cord, and dynorphin, enkephalin and SP have been mapped in the rat brain (Guenther et al., 2011; Hanrieder et al., 2011; Kallback et al., 2012; Ljungdahl et al., 2011) . Furthermore, PEP-19 was found to decrease after 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in mice (Skold et al., 2006) . However, the current study substantially increases the number of neuropeptides that can be simultaneously imaged and improves lateral resolution.
The MALDI-MSI approach used in this study was highly successful in mapping numerous neuropeptides in rat and primate brains. Distributions of the neuropeptides observed are consistent with distributions observed in previous studies using other techniques, such as immunohistochemistry (Fallon and Leslie, 1986; Haber and Elde, 1982; Jennes et al., 1982; Reiner et al., 1999; Shults et al., 1984) . These studies provide confirmatory validation of the MALDI-MSI technique.
Analysing the distribution and abundance of neuropeptides is important for elucidating changes in their profiles in neurological disorders. We sought to map how neuropeptides are affected in the basal ganglia circuitry in a PD model. Correct execution of voluntary movement requires complex regulation of neural signals within the basal ganglia. In PD, the dopaminergic projections from the SNc to the striatum degenerate, which affects downstream signalling within the basal ganglia. Most striatal neurons can be characterised by expression of either dopamine receptor 1 (D1) or dopamine J o u r n a l P r e -p r o o f receptor 2 (D2). Striatal neurons that highly express D1 receptors have been shown to project to the substantia nigra pars reticulata (SNr) and the GPi in what is known as the direct signalling pathway; and the neurons that highly express D2 receptors project to the GPe in the indirect pathway (Lang and Lozano, 1998) . Neurons involved in the direct pathway express SP and dynorphin neuropeptides, while those involved in the indirect pathway express enkephalins (Gerfen and Young, 1988) . Analysis of neuropeptide alterations in different brain regions in PD models and during L-DOPA treatment will likely improve understanding of perturbations of neuropeptide signalling associated with PD and similar disorders.
In this study, we detected significant alterations in multiple neuropeptides caused by 6-OHDA lesioning and L-DOPA treatment. The MALDI-MSI method successfully revealed effects of these treatments on neuropeptides in specific brain regions, showing that neuropeptides in the CPu are more affected by the 6-OHDA lesioning, while those in the GP are more affected by the L-DOPA treatment.
We observed increases in levels of several PENK-derived neuropeptides in the 6-OHDA lesioned CPu, corroborating findings from previous mRNA studies (Capper-Loup and Kaelin-Lang, 2013; Gerfen et al., 1991; Marin et al., 2015; Sgroi et al., 2016) . In the GP, we also observed increases in several PENK-derived peptides in the lesioned hemisphere compared to the intact hemisphere in both saline and L-DOPA treated rats. The increases in levels of PENK neuropeptides during PD are thought to be protective, and may result from compensatory responses to loss of dopamine neurons (Bissonnette et al., 2014) . For instance, over-expression of proenkephalin in the striatum or injection of enkephalin µ-or δ-opioid receptor agonists in the globus pallidus in PD models leads to increased locomotion (Bissonnette et al., 2014; Dewar et al., 1985) . In addition, treatment of cultured dopaminergic neurons with a δ-opioid receptor agonist is protective against 6-OHDA toxicity (Borlongan et al., 2001) .
We also found that L-DOPA treatment affected enkephalin neuropeptide levels. We observed reductions in levels of several PENK-derived peptides in the GP and LH in both lesioned and unlesioned hemispheres of L-DOPA-treated rats. To our knowledge, such reductions in levels of PENK-derived neuropeptides following L-DOPA treatment have not been previously reported, despite J o u r n a l P r e -p r o o f Journal Pre-proof numerous studies of effects of L-DOPA treatment on neuropeptides. This may be at least partly because many studies have relied on in situ hybridization to quantify levels of PENK mRNA, which does not reflect levels of neuropeptides after the complex post-translational processing that occurs, or differential effects of the treatment on PENK-derived neuropeptides (Cenci et al., 1998; Marin et al., 2015; Sgroi et al., 2016) . Furthermore, most studies have focused on the effects of L-DOPA in the striatum, as it is one of the primary structures that receives dopaminergic neurons projecting from the substantia nigra (Cenci et al., 1998; Marin et al., 2015; Sgroi et al., 2016) . However, the GP is also a crucial structure for regulating locomotion through the basal ganglia pathway, thus understanding the role of enkephalin neuropeptides in this region is highly important for fully understanding the circuitry impacted in PD.
Further investigation is required to fully understand why L-DOPA treatment affects enkephalin levels in the GP. Neurons in the GP that contain proenkephalin mRNA also express dopamine D2 receptors and may be affected by dopaminergic neurons projecting directly from the substantia nigra to this region (Hoover and Marshall, 2002; Rommelfanger and Wichmann, 2010) . The neurons in the GP that contain proenkephalin mRNA have also been shown to be stimulated by a dopamine D2 receptor antagonist (Hoover and Marshall, 2002) . Therefore, during L-DOPA treatment, the increased levels of dopamine could lead to reduced stimulation of proenkephalin neurons and reduced levels of enkephalins in the GP, as observed in this study.
In this investigation, we observed significant increases in PDYN neuropeptides in the GP and CPu of the lesioned hemispheres in L-DOPA treated rats. An increase in dynorphin mRNA expression following L-DOPA treatment has been consistently found in a number of studies, and associated with L-DOPA induced dyskinesia (Cenci et al., 1998; Hanrieder et al., 2011; Sgroi et al., 2016; Tel et al., 2002) . It is unclear whether dynorphin neuropeptides are beneficial or detrimental in PD and L-DOPA induced dyskinesia (Sgroi et al., 2016; Wang et al., 2012) . However, previous studies found that behavioural impairments were more severe in mice lacking the prodynorphin gene in an MPTP mouse model of PD, than in PDYN wild-type mice (Wang et al., 2012) . We also observed a significant decrease in dynorphin B in the 6-OHDA lesioned LH in saline treated rats, but not in L-DOPA treated J o u r n a l P r e -p r o o f Journal Pre-proof rats. Dynorphins in the LH decrease firing of dopaminergic neurons that project from the ventral tegmental area to the ventral striatum in the mesolimbic pathway (Baimel et al., 2017) . The mesolimbic pathway is known to be affected in PD patients leading to cognitive symptoms such as impaired reward-related learning, which is reversed by L-DOPA therapy (Frank et al., 2004) . The reduced dynorphin B levels we observe in the lesioned LH may be a compensatory mechanism to increase dopamine firing to normalise impairments in the reward pathway.
Results of the MALDI-MSI analysis of SP (1-11) presented here are also consistent with previous findings of reductions in levels of mRNA encoding protachykinin-1 in PD models (Capper-Loup and Kaelin-Lang, 2013; Gerfen et al., 1991; Marin et al., 2015; Sgroi et al., 2016) . We found that levels of SP in the 6-OHDA lesioned CPu were significantly reduced in the saline-treated control rats, but not those treated with L-DOPA, suggesting that L-DOPA can normalize some of the 6-OHDA-induced reduction of SP. However, SP levels in the GP and LH were significantly reduced in the lesioned hemisphere of both saline treated and L-DOPA treated animals. There have been conflicting indications of whether SP contributes to or decreases the degeneration of dopaminergic neurons in PD and the onset of L-DOPA-induced dyskinesia. For example (Wang et al., 2014) , found that mice lacking the protachykinin gene were protected from degeneration of dopaminergic neurons after MPTP treatment, and treatment with a NK1 receptor antagonist can reportedly delay symptoms of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats (Thornton et al., 2014) . In contrast, some studies have proposed SP as a potential therapeutic agent in the treatment of PD due to its protective effects against dopamine depletion (Krasnova et al., 2000; Wang et al., 2015) .
The increased neurotensin levels in the GP after 6-OHDA lesioning were most prominent in the distinct dorsal sub-region of the GP. This novel observation is likely difficult to detect using other methods that involve the dissection and homogenisation of brain samples. The GP receives dopaminergic projections from the SN, and neurotensin is known to co-localize with dopamine and can modulate the dopaminergic system (Martorana et al., 2003) . Neurotensin levels are likely increased in models of PD in a compensatory response to dopamine reduction. Thus, previous studies J o u r n a l P r e -p r o o f have investigated neurotensin as a treatment to alleviate symptoms in PD models and reported promising results (Jolicoeur et al., 1991; Xue et al., 2009) .
In summary, the method introduced here substantially enhanced the detection threshold and number of neuropeptides that can be analysed by MALDI-MSI. This sample preparation technique allows simultaneous mapping of over 20 neuropeptides across the brain, while limiting delocalization. Furthermore, the sample preparation method was found to be highly reproducible and suitable for high lateral resolution imaging. Application of MALDI-MSI to analyse a unilateral 6-OHDA rat PD model also demonstrated the method's capacity for mapping previously known and unknown alterations in neuropeptides caused by dopaminergic neurodegeneration and treatment with L-DOPA.
J o u r n a l P r e -p r o o f neuropeptides in a single hemisphere of the coronal primate brain at level -2.5 from the anterior commissure (Martin and Bowden, 1996) . Through MALDI-TOF-MSI analysis, 11 enkephalins (a), seven dynorphins (b), neurokinin A (NK A), two substance P neuropeptides (c), and four other neuropeptides (d) were detected. Annotations: Amg, amygdala; Put, putamen; GPe, external globus pallidus; GPi, internal globus pallidus; HCd, head of caudate nucleus; LH, lateral hypothalamus; StT, nucleus of stria terminalis; and TCd, tail of the caudate nucleus. Scale bar = 10 mm. Fig. 2 . Neuropeptide distribution in the rat brain determined by MALDI-MSI. MALDI-TOF-MSI images of neuropeptides in a coronal rat brain section at bregma -2.04 (Paxinos and Watson, 2014) .
Figure Legends
The neuropeptides detected included several enkephalins (a), dynorphins (b), tachykinins (c), and other neuropeptides (d). Annotations: CPu, caudate putamen; GP, globus pallidus; Hip, hippocampus;
Hyp, hypothalamus. Scale bar = 2 mm Fig. 3 . High lateral resolution imaging of neuropeptides in the primate and rat brain. MALDI-TOF-MSI heat maps of neuropeptides in the primate brain, -3 mm from anterior commissure (Martin and Bowden, 1996) at 25 μm lateral resolution (a). Annotations: Amg, amygdala; Put, putamen; BCd, body of the caudate nucleus; GPe, external globus pallidus; Gpi, internal globus pallidus; SI, substantia innominate; TCd, tail of the caudate nucleus. Scale bar = 2 mm MALDI-TOF-MSI heat maps of neuropeptides in the rat brain, -2.76 mm from bregma (Paxinos and Watson, 2014) at a lateral resolution of 15 μm (b). Annotations: Amg, amygdala; Cpu, caudate putamen; GP, globus pallidus;
GrDG, granule cell layer of dentate; ic, internal capsule; LH, lateral hypothalamic area; Lmol, lacunosum moleculare layer; MoDG, molecular layer of dentate gyrus; PoDG, polymorph layer of dentate gyrus; PVP, paraventricular thalamic nucleus; stratum lucidum of hippocampus; st, stria terminalis. Scale bar = 1 mm.
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